Role of Gabapentin in Spinal Muscular Atrophy

Abstract

Recent studies suggest that gabapentin has a neuroprotective effect in experimental models of motoneuron disease. We carried out a multicenter, randomized, controlled trial of gabapentin versus no treatment in 120 patients with type II or III spinal muscular atrophy for 12 months. We assessed maximum voluntary isometric contraction with a handheld myometer and calculated an arm megascore (summing elbow flexion, hand grip, and three-point pinch scores), and a leg megascore (summing knee flexion, knee extension, and foot extension scores). Forced vital capacity and timed tasks were also evaluated. Arm megascore improved by at least 30% in 24.6% of treated and 16.9% of untreated patients (relative risk = 1.45; 95% confidence interval = 0.71—2.97). The leg megascore improved by at least 30% in 37.7% of treated and 20.3% of untreated patients (relative risk = 1.85; 95% confidence interval = 1.02—3.37). We conclude that gabapentin produced a significant improvement in leg megascore at 6 months, which was more evident at 12 months, with a trend for improvement in arm megascore at 12 months. The treatment had no effect on forced vital capacity or timed functional tests. (J Child Neurol 2003;18:537—541).

Get full access to this article

View all access options for this article.

References

Munsat TL : Workshop report, International SMA collaboration. Neuromusc Disord 1991;1:81.

Lefebvre S. , Burglen L. , Reboullet S. , et al: Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80:155—165.

Choi DW : Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623—634.

Greensmith L. , Vrbova G. : Possible strategies for treatment of SMA patients: A neurobiologist's view. Neuromusc Disord 1995; 5:359—369.

Rothstein JD , Tsai G. , Junel RW , et al: Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28:18—25.

Rosen DR , Siddique T. , Patterson D. , et al: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993 ;362:59—62.

Taylor CP : Mechanisms of action of gabapentin. Rev Neurol 1997;153(suppl 1):S39—S45.

Merlini L. , Mazzone E. , Solari A. , et al: Reliability of hand-held dynamometry in spinal muscular atrophy. Muscle Nerve 2002;26:64—70.

Russman BS , Buncher CR , Whitie M. , et al: Functional changes in spinal muscular atrophy II and III. Neurology 1996;47:973—976.

10.

Iannaccone ST , Russman BS , Browne RH , et al: Prospective analysis of strength in spinal muscular atrophy. J Child Neurol 2000;15:97—101.

11.

International Classification of Impairments, Activities and Participation : A Manual of Dimensions of Disablement and Health. Available at: http://www.who.org/msa/mnh/ems/icdih/ntroduction.htm (accessed March 27, 2003).

12.

Miller RG , Moore DH , Dronsky V. , et al: A placebo-controlled trial of gabapentin in spinal muscular atrophy. J Neurol Sci 2001; 191:127—131.